Medical University of South Carolina Charleston HFpEF Conference 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: cardiovascular specialists, heart failure specialists, cardiovascular advanced practice providers (NP or PA), internists, family physicians

+ Sample video: contact me for sample video

+ Information:

There are now more patients who have Heart Failure with preserved Ejection Fraction (HFpEF) than those with reduced Ejection Fraction (HFrEF). Making the diagnosis of HFpEF is more challenging than HFrEF as many commonly used screening tools such as physical examination, echocardiography and measurement of natriuretic peptide levels are less sensitive and specifc in this population. Most importantly, no therapies have yet been shown to improve major cardiovascular outcome (i.e. reductions in hospitalization rates or lower mortality). Several ongoing studies are evaluating novel treatments for this disorder.

Learning Objectives

At the completion of this conference, participants should be able to:

1. Review the latest evidence on the optimal choices of diuretics in heart failure.
2. Discuss new approaches to giving advice about sodium and fuid restriction in patients with heart failure.
3. Efectively prescribe medications for weight management in patients with HFpEF
4. Engage in shared decision making with your patients about the value of newer treatments
5. Discuss the mechanisms of diastolic dysfunction in patients with HFpEF
6. Design and implement a HF clinic for follow up of recently hospitalized HF patients

Target Audience

This course is intended for cardiovascular specialists, heart failure specialists, practicing cardiologists, cardiovascular advanced practice providers (NP or PA), internists, family physicians, pharmacist, cardiovascular nurses, critical care nurses, and industry representatives.

 

+ Topics:

1. Reaching a New Peak – Results of SUMMIT and GLP-1 Agonists in HFpEF

2. No Longer Limited Options – New and Emerging Treatments for HFpEF

3. Key Issues Surrounding Remote Monitoring in HFpEF in 2025 – Implementation, Pressure vs. Volume, Biomarkers vs. Hemodynamics

4. Phenotyping Heart Failure with Preserved Ejection Fraction – How Do We Make It Clinically Relevant

5. Etiology, Evaluation and Management of Iron Deficiency in Heart Failure

6. The Original HFpEF Contemporary Approach to Diagnosis and Treatment of Hypertrophic Cardiomyopathy (tập tin Word)

7. The Perils and Pearls of Polypharmacy in HFpEF – Clinical and Financial Toxicity

8. Is it Cardiac, Pulmonary, or Both The Challenge of Diagnosing and Treating PH with Comorbidities

9. The Emerging Role of Device Therapies for HFpEF

10. Top HFpEF Paper of the Year

11. Should We Transplant Patients with HFpEF

12. HFpEF is a Metabolic Disease – Changing Treatment Paradigms

13. From Inflammation to Dysfunction – Autoimmune Disease as a Substrate for HFpEF

14. Mortimer, We’re Back – The Re-Emergence of MRA’s in HFpEF

15. The Latest in Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis – Stopping the Epidemic

16. How Do SGLT2 Inhibitors and GLP1 Agonists Really Work in Patients with HFpEF

17. Pearls Learned from Running an APP Lead Heart Failure Clinic

18. Artificial Intelligence for the Diagnosis and Management of HFpEF

19. Post-PE Syndrome – HFpEF Mimicker – How to Distinguish and Treat

20. Cardiac MRI for HFpEF; Can We Help

21. Update on Optimizing Diuretic Therapy in Patients with HFpEF

22. Defining HFpEF – Is the Wedge Still the Cutting Edge

23. -Omic Precision Medicine for HFpEF

24. Management of HFpEF In Patients with Advanced Kidney Disease and End-Stage Renal Disease

25. Panel Discussion – How Do We Continue & Speed Up The Current Progress That Has Been Made In The Treatment Of HFpEF Over